Melanoma: Targeting signaling pathways and RaLP

Luigi Pasini, Margherita Y. Turco, Lucilla Luzi, Ewa Aladowicz, Ernesta Fagiani, Luisa Lanfrancone

Research output: Contribution to journalArticle


Background: Metastatic melanoma remains one of the most aggressive forms of cancer, with a survival expectation of above six months only in rare cases. Despite advances in the characterization of the underlying molecular pathways and in the development of specific targeted treatments, available chemo- and immuno-therapy are unable to prolong survival significantly in advanced-stage melanoma. Rai like protein (RaLP) is a newly identified Src homology 2 domain containing (Shc) family member selectively expressed during the transition to metastatic melanoma and thus is a potential melanoma-specific drugable target. Objective: To summarize progress in the ongoing therapeutic approaches to metastatic melanoma and discuss RaLP as a potential novel therapeutic target. Methods: Current understanding of the major signaling pathways involved in melanoma metastatization and of the corresponding pharmacological inhibitors is discussed. Conclusion : RaLP might represent a new drugable target for the treatment of metastatic disease.

Original languageEnglish
Pages (from-to)93-104
Number of pages12
JournalExpert Opinion on Therapeutic Targets
Issue number1
Publication statusPublished - Jan 2009


  • Metastatic melanoma
  • RaLP
  • Shc family
  • Targeted inhibitors

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Fingerprint Dive into the research topics of 'Melanoma: Targeting signaling pathways and RaLP'. Together they form a unique fingerprint.

  • Cite this